Sign In
Buy NURO
$4.58
+0 (+0%)
At Close: Jul 30, 2025
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
08:00am, Tuesday, 12'th Mar 2024
NURO stock price has declined 99% since its IPO Gozani has received compensation of over $10 million since the IPO Gozani was charged by the FTC for various wrongdoings at NURO Gozani apparently perso
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
08:00am, Monday, 04'th Mar 2024
- Stock trades significantly below its net cash per share - Questions the Board's ability and/or desire to create shareholder value - Notes tremendous destruction of shareholder value under company's
NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript
11:55am, Thursday, 22'nd Feb 2024
NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
07:00am, Thursday, 22'nd Feb 2024
WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
09:00am, Thursday, 15'th Feb 2024
NeuroMetrix plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
09:00am, Tuesday, 13'th Feb 2024
WOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
09:43am, Monday, 08'th Jan 2024
NeuroMetrix announced today that the Company's Chairman and CEO, Dr. Shai N. Gozani will present at the Emerging Growth Conference on January 10, 2024.
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
09:00am, Tuesday, 12'th Dec 2023
WOBURN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patient
NeuroMetrix noted publication of results from a NIH-funded clinical trial of Quell. The paper has been electronically published in The Journal of Pain.
NeuroMetrix Announces One-for-Eight Reverse Stock Split
09:00am, Monday, 20'th Nov 2023
WOBURN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on Nove
NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023
09:00am, Monday, 30'th Oct 2023
WOBURN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on Wednesday, November 1, 2023.
NeuroMetrix Inc. (NURO) Q3 2023 Earnings Call Transcript
10:22am, Friday, 27'th Oct 2023
NeuroMetrix Inc. (NASDAQ:NURO ) Q3 2023 Results Conference Call October 26, 2023 8:00 AM ET Company Participants Thomas Higgins - SVP & CFO Shai Gozani - Chairman & CEO Operator Good morning, and welc
NeuroMetrix Reports Q3 2023 Business Highlights
07:00am, Thursday, 26'th Oct 2023
WOBURN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023.
NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call
11:13am, Monday, 23'rd Oct 2023
NeuroMetrix, Inc. announced today that it plans to issue its Q3 2023 business and financial highlights on October 26, 2023 at 8:00 a.m., Eastern Time.
WOBURN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA).
